Craniopharyngioma
Conditions
Keywords
BRAF mutation, Dabrafenib, Trametinib, Neoadjuvant, Postoperative
Brief summary
Subjects with papillary craniopharyngioma harboring a BRAF mutation will be treated with a BRAF + MEK inhibitor (dabrafenib + trametinib) after informed consent. Study participants will be administered oral dabrafenib and trametinib until maximal tumor volume reduction assessed by MRI. Progression free survival, cognition, ophthalmologic status, hypothalamic status and quality of life will be assessed 1 year after initiation of study treatment
Detailed description
Background. Papillary craniopharyngioma harbours a BRAF mutation in 90% of cases. Treatment with BRAF + MEK (mitogen activated protein kinase ) inhibitors (dabrafenib + trametinib) may prevent patients from undergoing surgery with a high risk of serious side effects, or provide an additional treatment option when further surgery is not advised. Study intervention Subjects with newly diagnosed craniopharyngioma where radical surgery is not considered adequate or patients with recurrence of craniopharyngioma where further surgery is not considered possible without serious sequelae will be asked for informed consent Study participants are treated continuously with dabrafenib and trametinib orally, until maximal tumor shrinkage. Evaluation is done by MRI to measure tumor volume, as well as assessment of performance status, quality of life, cognition, ophthalmologic status, performance status and hypothalamic status. Study type The study is a Phase II, single armed, open label and multicenter study Study drugs are Dabrafenib (Tafinlar) and trametinib (Mekinist) Primary outcome To evaluate tumor response in the form of reduced tumor volume on MRI in patients with papillary craniopharyngioma during treatment with dabrafenib and trametinib. Secondary outcomes To evaluate dabrafenib and trametinib treatment for the following aspects: * response according to RECIST Duration of response for patients treated without subsequent surgery * how many patients become operable after neoadjuvant treatment * progression-free survival after 1 and 2 years * quality of life during and after treatment The effect of treatment on vision, cognition and hypothalamic effects Exploratory outcomes Levels of circulating BRAF Trial population 25 patients Trial duration Participants are treated with the study treatment for at least one year if the treatment is well tolerated, to maximum tumor reduction, or longer according to the investigators´s assessment. Treatment is discontinued in case of progression, unacceptable toxicity or at the request of the patient.
Interventions
DRUGOral dabrafenib and trametinib
Neoadjuvant or postoperative treatment of patients with verified BRAF mutated papillary craniopharyngioma
Sponsors
Novartis
Eva Marie Erfurth, MD, PhD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase 1, single arm, open label, multicenter.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically verified papillary craniopharyngioma. 2. BRAF mutated V600E (valine 600 glutamine), verified immunohistochemically and by molecular genetic analysis 3. Newly diagnosed tumor, or recurrence after previous surgery, where surgery is not considered to be able to be performed radically without the risk of serious or permanent sequelae. 4. Age over 18 years 5. Functional status according to ECOG (Eastern Cooperative Oncology Group performance status) 0-2 6. Adequate organ function: neutrophils\> 1.5 x 109 platelets\> 100 x 109 creatinine \<1.5 x ULN (upper limit of normal) or creatinine clearance \<45 ml / min bilirubin \<1.5 x ULN ASAT (aspartate aminotransferase) / ALAT (alanine aminotransferase) \<2.5 x ULN 7. Ability to understand and give informed consent. 8. Previous cancer, which does not require current treatment is allowed. 9. The patient agrees to use an adequate method to avoid pregnancy.
Exclusion criteria
1. Ongoing treatment in another drug study or other experimental treatment. 2. Previous treatment with BRAF or MEK inhibitors. 3. Hypersensitivity to study drugs. 4. Ongoing treatment with non-authorized drugs, (strong inducers of CYP2C8 or CYP3A4). If the patient is on unauthorized drugs, they must be discontinued at least 14 days before inclusion. 5. Known cardiovascular disease where treatment with MEK inhibitors is considered inappropriate, eg severe heart failure, prolongation of QT time, uncontrolled arrhythmia, recent (\<6 months) cardiac infarction, uncontrolled hypertension. 6. Active bleeding; intracranial hemorrhage last 4 weeks before inclusion. 7. Thromboembolic disease last 6 months and unstable anticoagulant treatment less than 4 weeks before inclusion. 8. Women who are pregnant or breastfeeding. 9. Previous central serous retinopathy or retinal vein occlusion. 10. Previous uveitis or iritis last 4 weeks before inclusion. 11. Surgery within the last 3 weeks. 12. For postoperative patients; radiation therapy within the last 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor response | 1 month to 5 years (sliding timepoints) | To evaluate tumor response measured as maximally reduced tumor volume on MRI during treatment with dabrafenib and trametinib. Maximally reduced volume is defined as the time point where no further reduction of tumor volume can be observed |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response ratio | 1 year after initiation of study treatment | Response ratio according to RECIST |
| Response duration | From time of study drug discontinuation to time of observed increased tumor volume assessed up to 1 year | Duration of response for patients treated without subsequent surgery |
| Operability after neoadjuvant trial treatment | 1 year after initiation of study treatment | Number of patients which become operable after neoadjuvant treatment |
| Progression-free survival 1 year | 1 year | Defined as unchanged or diminished tumor volume |
| Progression-free survival 2 years | 2 years | Defined as unchanged or diminished tumor volume |
| Opthalmologic status after treatment | 1 year | Opthalmologic status assessed as compound measure of visual acuity and visual field defects 1 year after initiation of treatment and compared to baseline |
| Hypothalamic status after treatment | 1 year | Hypothalamic status assessed as compound measure of pituitary and hypothalamic status 1 year after initiation of treatment and compared to baseline |
| QOL after treatment | 1 year | Quality of life assessed by EQ5D5L (EuroQual 5 dimensions 5 levels) at 1 year after start of study treatment and compared to baseline |
| Cognitive status after treatment | 1 year | Cognitive status assessed by CNS (central nervous system) Vital Signs 1 year after initiation of treatment and compared to baseline |
Other
| Measure | Time frame | Description |
|---|---|---|
| Levels of circulating mutated BRAF | 1 week after initiation of trial treatment | BRAF assessed by plasma analysis and compared to baseline levels |
| Levels of circulating of mutated BRAF | 3 months after end of trial treatment | BRAF assessed by plasma analysis and compared to baseline levels |
Countries
Sweden
Contacts
Primary ContactEva Marie Erfurth, MD. PhD.
Backup ContactSara Kinhult, MD. PhD.
Outcome results
None listed